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Abstract
IFIH1 (interferon induced with helicase C domain 1), also known as MDA5 (melanoma differentiation-associated protein 5), is
one of a family of intracellular proteins known to recognise viral RNA and mediate the innate immune response. IFIH1 is
causal in type 1 diabetes based on the protective associations of four rare variants, where the derived alleles are predicted
to reduce gene expression or function. Originally, however, T1D protection was mapped to the common IFIH1 nsSNP,
rs1990760 or Thr946Ala. This common amino acid substitution does not cause a loss of function and evidence suggests the
protective allele, Ala
946, may mark a haplotype with reduced expression of IFIH1 in line with the protection conferred by the
four rare loss of function alleles. We have performed allele specific expression analysis that supports this hypothesis: the T1D
protective haplotype correlates with reduced IFIH1 transcription in interferon-b stimulated peripheral blood mononuclear
cells (overall p=0.012). In addition, we have used multiflow cytometry analysis and quantitative PCR assays to prove
reduced expression of IFIH1 in individuals heterozygous for three of the T1D-associated rare alleles: a premature stop
codon, rs35744605 (Glu627X) and predicted splice variants, rs35337543 (IVS8+1) and rs35732034 (IVS14+1). We also show
that the nsSNP, Ile923V, does not alter pre-mRNA levels of IFIH1. These results confirm and extend the new autoimmune
disease pathway of reduced IFIH1 expression and protein function protecting from T1D.
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Introduction
Susceptibility to T1D was originally mapped to a common SNP,
rs1990760 in the IFIH1, FAP, GCA and KCNH7 region of
chromosome 2q24 [1]. Further SNP typing revealed several
variants across the region in high linkage disequilibrium (LD)
(Figure S1) and statistically indistinguishable for T1D association.
However, the nsSNP, rs1990760 or Thr946Ala, in exon 15 of
IFIH1, was considered the most likely functional candidate due to
the highly conserved amino acid substitution and the role of IFIH1
in innate immunity, including mediating type 1 interferon
production, which has been consistently reported to be associated
with type 1 diabetes [1,2,3]. More recently, four rare or low
frequency variants within IFIH1 were associated with T1D,
indicating the gene is causal [4] (Figure S2 and Table S1). The
four variants share a common feature: the minor alleles, which
have predicted functional implications, are protective for T1D,
implying that reduced expression or function of IFIH1, which is
known to be a receptor for viral RNA, protects against T1D. The
common variant or haplotype is still associated with T1D after
taking into account the rare variants, and vice versa (Table S1).
Experimental analysis of the common nsSNP, rs1990760/
Thr946Ala, has revealed that the amino acid substitution does not
alter the function of IFIH1, at least within the parameters and
sensitivity of the assay employed [5], and evidence suggests
rs1990760/Thr946Ala genotype correlates with mRNA levels [6].
In addition, it is the conserved allele that encodes Ala
946, the
presumed functional amino acid, not the derived allele, as is the
case for the four low frequency variants (Table S1). Therefore, we
hypothesise that Ala
946 is not causal itself but a marker for
common haplotypes carrying functional variants that reduce
IFIH1 transcription compared to other haplotypes with normal or
higher expression. Two groups have previously attempted to
correlate genotype at rs1990760/Thr946Ala with expression of
IFIH1 with only one identifying an association [6,7]. These studies
used quantitative PCR (qPCR) which has limited sensitivity for
detecting small differences in transcript levels between different
individuals with defined IFIH1 genotypes. Therefore, we used
allele-specific expression (ASE) analysis to detect transcriptional
bias within individuals using genomic DNA from the same
individual as a control. Most recently Zouk et al. [8] also applied
an ASE approach to test the same hypothesis at IFIH1 and found
no evidence for allelic imbalance at rs1990760. Here, we have
extended these analyses to induced IFIH1 RNA using additional
ASE assays and obtained positive results.
The two exonic T1D associated SNPs, Ile923Val and Glu627X,
reduce the type I interferon response to Poly I:C, a viral dsRNA
mimic, in complementation assays providing evidence of their
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bioresource (www.cambridgebioresource.org.uk) that are hetero-
zygous for one of the four T1D associated low frequency variants.
Using qPCR and quantitative multicolor flow cytometric analysis,
we have measured the protein expression, splicing and transcript
levels to prove the functionality of the rare T1D variants in human
immune cell subsets.
Results
Allele specific expression of the common IFIH1 T1D
haplotype
We used a sequencing based ASE assay [9] to correlate the pre-
mRNA level of IFIH1 with the common haplotypes marked by the
T1D associated nsSNP Thr946Ala. Subjects selected for ASE
analysis had no low frequency IFIH1 T1D alleles and were
heterozygous at both common IFIH1 nsSNPs, Thr946Ala
(rs1990760 A/G) and A843H (rs3747517 C/T). Phasing geno-
types of 9,970 control samples (using SNPHAP, http://www-gene.
cimr.cam.ac.uk/clayton/) revealed the T1D protective minor
alleles of rs1990760 and rs3747517 always reside on the same
haplotype in individuals heterozygous at both SNPs. Genomic and
cDNA from each donor was amplified, sequenced and peak
heights analysed and normalised using the surrounding peaks [9].
Owing to concerns over biases caused by RNA secondary
structure [10], cDNA was synthesised using PBMC purified pre-
mRNA, poly A selected by priming with oligo-dT and using total
RNA fragmented and primed using random hexamers.
In nine samples no allelic specific bias for the common IFIH1
T1D associated haplotype was observed within the PBMC pre
mRNA of the poly A selected samples (p=0.12) or the fragmented
cDNAs (p=0.60) using the two SNP assays for rs1990760 and
rs3747517 (Figure S3).
Stimulation of PBMCs with IFN-b induces the transcription of
IFIH1 [11] and a positive feedback loop, through IFN regulatory
factor 7, induces IFN-b expression [12,13]. On stimulation with
1,000 U/ml IFN-b we measured a 27 fold and 40 fold induction of
IFIH1 and IFN-b transcription respectively (Figure S4). We
hypothesised that the regulatory loop not only increases IFIH1
expression, but may also amplify any transcriptional bias, if
present.
Assays for rs1990760 and rs3747517 were used to measure the
allelic bias in eight oligo-dT primed pre mRNA samples from
PBMCs stimulated with IFN-b for 4 hours. To provide additional
ASE data, an assay was designed for a third IFIH1 SNP,
rs13023380. In all ASE individuals the minor allele of rs13023380
(G) was on the T1D protective haplotype, also marked by the
minor alleles of rs1990760 (G) and rs3747517 (T).
ASE was observed in IFIH1 poly A selected pre mRNA from
INF-b stimulated PBMCs using the rs3747517 and rs13023380
SNP assays (Figure 1). The T1D associated haplotype correlated
with reduced transcription of IFIH1 (overall sign-ranked test
p=0.012). Fragmenting RNA prior to cDNA synthesis does not
alter the ASE observed at rs1990760 (p=0.48)(Figure S5).
The rare IFIH1 SNPs associated with T1D are functional
The two T1D-associated intronic SNPs within IFIH1,
rs35337543 (IVS8+1) and rs35732034 (IVS14+1), alter the 59
base of intron 8 and intron 14 consensus splice sequences,
respectively, and were predicted to alter splicing of the intron [4].
We recalled six healthy donors, from the Cambridge BioResource,
two individuals with no known rare IFIH1 variants, two
individuals heterozygous for rs35337543 (IVS8+1) and two
individuals heterozygous for rs35732034 (IVS14+1). qPCR assays
were designed to measure the level of spliced and unspliced
transcript, by designing primer pairs and probes specific to the
IFIH1 pre-mRNA and mRNA at the appropriate splicing
junction. The qPCR data indicated that PBMCs from individuals
heterozygous for the splice SNPs had more pre-mRNA transcript
and less mRNA transcript compared to the control donor at these
splicing junctions (Figure 2). These data confirm that the two
SNPs, rs35337543 (IVS8+1) and rs35732034 (IVS14+1), result in
aberrant splicing of the IFIH1 transcript.
The T1D-associated IFIH1 SNP, rs35744605 (Glu627X),
introduces a premature stop codon into the transcript. Using the
mRNA qPCR assays described above we measured the levels of
transcript within individuals heterozygous for the SNP,
rs35744605 (Glu627X). The premature stop codon did not alter
the level of IFIH1 mRNA detected within resting human PBMC
(Table S2). This is perhaps not unexpected since nonsense
mediated decay (NMD) of transcripts containing premature stop
codons is initiated during the pioneering round of translation
within the cytoplasm. Resting immune cells do not express high
levels of IFIH1 (Figure S7) suggesting the low turnover of
translation results in small differences in mRNA levels between
individuals with Stop
627 and Glu
627, and these are undetectable by
qPCR.
To detect the reduced expression of IFIH1 due to the premature
stop codon we measured the level of the IFIH1 protein within
cells. We developed an intracellular staining protocol to detect
Figure 1. Allele specific expression of IFIH1 pre mRNA transcript for the common T1D haplotype in IFN-b stimulated PBMCs. The
mean allelic ratio is a measure of the ratio of the sequencing trace peak heights for the heterozygous SNP within genomic and cDNA from each
individual (overall sign-rank p=0.012).
doi:10.1371/journal.pone.0012646.g001
IFIH1 ASE
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IFIH1 within subsets of peripheral immune cells. IFIH1 protein is
detected in resting monocytes, B and T cells and upon stimulation
with IFN-b (Figure S6 and S7). To demonstrate that the SNP,
rs35744605 (Glu627X), causes reduced expression of IFIH1, three
pairs of donors were assayed. Within each pair, one individual did
not carry any known IFIH1 variants and the other was
heterozygous for the stop codon SNP. IFIH1 expression was
reduced in cell subsets in individuals heterozygous for the stop
codon (Figure 3). The reduced expression observed in samples
heterozygous for rs35744605 (Glu627X) is amplified with IFN-b
stimulation within cell subsets (Figure S8) and in total protein
lysates of PBMCs (Figure S9).
Cells expressing constructs containing the rare nsSNP allele
Val
923 at rs35667974 (Ile923Val) have a reduced type I IFN
response to Poly I:C [5], indicating that this allotype reduces
function of IFIH1. To investigate if this T1D associated rare
nsSNP also alters expression or splicing of IFIH1 RNA within
human immune cells we used the qPCR assays described above to
measure pre-mRNA and mRNA levels in cDNA synthesised using
RNA purified from PBMCs of an individual selected to be
heterozygous for Ile923Val. Pre mRNA or mRNA levels did not
correlate with Ile923Val (Figure 4) suggesting that, within this
individual, Ile923Val did not alter expression of IFIH1 in a major
way. ASE analysis of pre-mRNA at Ile923Val did not show any
allelic imbalance (data not shown). Since Val
923 does not alter
dsRNA binding [5], we predict that the amino acid substitution
reduces the efficiency of IFIH1 interactions, possibly with
interferon-beta promoter stimulator protein-1 (MAVS, mitochon-
drial antiviral signaling protein, also known as IPS-1, VISA and
Cardif) during anti-viral signaling [14].
Discussion
IFIH1 (interferon induced with helicase C domain 1), also
known as MDA5 (melanoma differentiation-associated protein 5),
is one of a family of intracellular proteins known to recognise viral
RNA and mediate an immune response [15]. The IFIH1 receptor
is specific for the double stranded intermediate generated during
replication of single stranded, positive sense picornaviruses [16]
and negative sense Paramyxoviridae [17]. This, and the
established seasonality of T1D diagnosis, increasing incidence of
T1D [18] and reports that Coxsackie infection is associated with
T1D [19], suggest that several viruses may be involved in the
aetiology of the disease [3].
The verification of the predicted loss of function of the four rare
SNPs (here and Shigemoto T., et al. [5]) confirms that reduced
IFIH1 protein and function protects against T1D. We also
hypothesised that the protective allele of the common T1D nsSNP,
rs1990760, may mark haplotypes with reduced expression of
IFIH1, in line with the loss of function conferred by the protective
alleles of the low frequency T1D variants.
qPCR has limited sensitivity for detecting small differences in
transcript levels between individuals, and therefore, we used an
ASE method to measure allelic imbalance within individuals
heterozygous for SNPs that mark the T1D haplotype. Here we
present evidence that the protective T1D associated haplotype
correlates with reduced transcription of IFIH1 that is reproduc-
Figure 2. Detection of aberrant splicing of IFIH1 mRNA for the two rare SNPs predicted to alter splicing. Levels of IFIH1 pre mRNA and
spliced RNA transcript were measured using qPCR assays designed to the corresponding exon to intron and exon to exon sequence. The delta Ct is
calculated using the pre mRNA transcript Ct minus the mRNA transcript Ct. A larger delta Ct indicates more pre-mRNA and less mRNA transcript of
IFIH1. Donor 1 and 2 are control individuals, donor 3 and 4 heterozygous for rs35337543 (IVS8+1) and donor 5 and 6 are heterozygous for rs35732034
(IVS14+1).
doi:10.1371/journal.pone.0012646.g002
Figure 3. Reduced IFIH1 expression within monocytes, B and T
cells in donors heterozygous for the rare premature stop
codon SNP, rs35744605 (Glu627X). Mean fluorescent intensity
(MFI) of IFIH1 expression for each donor heterozygous for rs35744605 is
normalised to the MFI of the paired control individual.
doi:10.1371/journal.pone.0012646.g003
IFIH1 ASE
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(Figure 1).
No allelic bias was detected in resting PBMCs (Figure S3) possibly
due to the low levels of transcript available for amplification or that
the effect of allelic variation on IFIH1 transcription only manifests in
conditions of stimulation, stress or infection in vivo. Biological and/or
experimentalfactorscouldaccountforthe lackofbiasobservedatthe
SNP rs1990760. Interestingly, rs1990760 lies within exon 14 at the 39
of the gene while the SNPs rs3747517 and rs13023380 are towards
the 59 end of the gene. This observation may account for the
discordance between two of the previous attempts to correlate Ala
946
of rs1990760 with IFIH1gene expression by qPCR of un-fragmented
RNA hexamer primed cDNA [6,20]. One group did not observe an
expression difference using a quantitative PCR assay at the 39 end of
the gene [20], while the other study measured mRNA at the 59end of
the gene and showed lower IFIH1 expression for haplotypes bearing
Ala
946, a result consistent with ours [6]. We did not observe allelic
imbalance at rs1990760 using an ASE approach in steady state or
induced RNA, consistent with the recent null result from Zouk et al.
[8]. These results highlight the importance of analysing multiple
SNPs in a gene for ASE studies [21].
Further functional studies will help elucidate the mechanisms
by which normal or wild type function of IFIH1 predisposes to
pancreatic autoimmunity. IFIH1-mediated type 1 interferon respons-
es within monocytes, T and B cells could maintain the activation,
expansion or differentiation of autoreactive T cells [4]. In addition,
normal or activated anti viral responses in T1D susceptible
individuals could be permissive for apoptosis of infected pancreatic
b cells, which express high levels of IFIH1 R N A ,a n di n d u c et y p e1
interferon signaling, increasing HLA class I expression on b cells,
thereby increasing CD8 T cell mediated destruction [2,3].
Materials and Methods
Donors and genotypes
Blood was collected from donors selected from a pre-genotyped
bioresource and processed within 4 hours (www.cambroidgebio
resource.rg.uk). Within each experiment samples were processed
in parallel using the same reagents. ASE donors were heterozygous
at rs1990760 and rs3747517 and heterozygous for rs13023380 in
the IFN-b stimulated ASE samples. Genotypes for all other donors
at the five IFIH1 SNPs are listed in Table S3.
Study ethics
Subjects were recruited from the Cambridge BioResource
(www.cambridgebioresource.org.uk) as part of the ‘Genes and
Mechanisms of Type 1 Diabetes’ study. The study has ethical
approval from the NHS Cambridgeshire Research Ethics
Committee. All data and samples are treated as confidential.
Blood and saliva samples are stored identified by a unique bar
code only and volunteers are free to withdraw from the project at
any time.
PBMC isolation and preparation of DNA and RNA
PBMCs were purified from heparinised blood diluted 1:1 in
phosphate buffered saline (PBS) (without Ca
2+ and Mg
2+, GIBCO,
Invitrogen). Fifteen ml aliquots of the diluted blood were layered
onto 10 ml aliquots of LympholyteH (Cedarlane Laboratories Ltd)
and were centrifuged at 8006g for 20 min at room temperature
with no brake. The PBMC layer was washed twice with PBS, with
centrifugation at 3006g for 10 min at 4uC.
Total RNA from PBMCs was extracted using TRIzolH Reagent
(Invitrogen) and DNaseI-treated using the RNeasy Mini kit
(QIAGEN), according to the manufacturers’ instructions. RNA
quality was assessed using a Bioanalyzer (Agilent technologies) and
quantitated using a NanoDrop spectrophotometer (Thermo
Scientific). Prior to cDNA synthesis the RNA was either left
unfragmented or fragmented using a chemical fragmentation
reagent according to the manufacturers protocol (Ambion). First
strand complementary DNA synthesis was carried out on 1 mgo f
RNA using Superscript
TM III RT kit and using either oligo-dT for
the un-fragmented or random hexamers (Invitrogen) for the
fragmented RNA samples. The 150–350 base-pair fragments of
cDNA primed using hexamer were selected using gel purification.
Genomic DNA was extracted from an aliquot of blood by
chloroform extraction.
Allele specific expression assays (ASE)
Primers flanking rs35667974, rs1990760 and rs13023380 were
used to amplify cDNA and genomic DNA by PCR using
AmpliTaq Gold
TM (ABI) in duplicate. For sequencing based
ASE, duplicate PCR products were mixed and gel purified,
sequenced using BigDye Terminator chemistry (Applied Biosys-
tems) and resolved using an Applied Biosystems 3730XL DNA
analyzer. Up to four sequence traces per PCR product were
analysed using PeakPicker software as described by Bing Ge [9]
and used to estimate the allelic ratio. The geometric mean of the
replicate allelic ratios was used in the Wilcoxon matched-pairs
signed-rank test [22] to ask if the distribution differed between the
matched genomic and cDNA sample pairs. The allelic ratios are
correlated within samples across SNPs, therefore the geometric
means of allelic ratios could be calculated across SNPs to perform
an overall test of whether the allelic ratio distribution of cDNA and
genomic differed, again using a Wilcoxon signed rank test.
Quantitative PCR assays (qPCR)
qPCR primers and probe were designed to the pre mRNA and
mRNA sequences flanking the SNPs rs35337543 and rs35732034
(Table S4). Probes were labeled with the fluorochrome FAM and
were quenched using TAMRA. qPCR assays contained 5 mlo f
1:10 dilution of oligo-dT primed cDNA, prepared as described
Figure 4. Levels of pre-mRNA and mRNA transcript of IFIH1 are
not altered by the rare nsSNP, rs35667974, Ile923Val. Delta Ct
calculated using the IFIH1 qPCR minus the single copy gene b2
microglobulin (B2M) qPCR. Donor 17 is the control individual and donor
18 is heterozygous for Ile923Val. E8-E10: exon 8 to exon 10 qPCR assay,
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ABI prism (ABI) and analysis was performed using SDS v2.1
software (ABI). qPCR reactions were run in duplicate and delta
Cts for the splice assays were calculated using the Ct of the pre
mRNA qPCR minus the Ct of the mRNA qPCR. Delta Ct for the
transcript level qPCRs were calculated using the IFIH1 qPCR Ct
value minus the single copy gene b2 microglobulin (B2M) qPCR
Ct value.
Flow cytometry
PBMCs were purified as described above. For IFN-b stimula-
tion, 1,000 U/ml of IFN-b (R&D Biosystems) was used per two
million PBMCs in X-VIVO 15 medium (Lonza Walkersville, Inc.)
supplemented with heat inactivated human AB serum (Sigma) at
37uC for 6 h or overnight.
PBMCs were stained for 30 min on ice using allophycocyanin
(APC)-conjugated anti-CD16, Alexa Fluor 700-conjugated anti-
CD3, PE-Cy7 conjugated anti-HLA-DR, PE-conjugated CD19
(BioLegend) and Pacific Blue-conjugated anti-CD14 (BD Biosci-
ences) according to maunufacturer’s instructions. Cells were fixed
at 37uC for 10 min using BD Phosphflow Fix Buffer 1 (BD
Biosciences) then permeabilised with ice cold BD Phosphflow
Perm Buffer III (BD Biosciences) for 30 min on ice. Cells were
washed with BD Pharmingen Stain Buffer (BD Biosciences) for
5 min at 5006 g, with an extra wash following permeabilisation
and intracellular staining. Cells were blocked and incubated with a
primary anti-IFIH1 rabbit polyclonal (Prestige) for 60 min on ice
and washed twice before addition of Alexa Fluor 488-conjugated
goat anti-rabbit IgG (Invitrogen) at 1:200 dilution for 30 min on
ice. Cells were analysed using a BD LSRII Flow Cytometer with
BD FACSDiVa Software (BD Biosciences) and mean fluorescence
intensity (MFI) data was obtained via FlowJo (Tree Star, Inc.).
Supporting Information
Table S1 Association analysis of each of the IFIH1 SNPs
contribution to T1D association in the region. Logistic regression
analysis was performed using a complete data set of 7,024 cases
and 8,844 control samples. The 1df test result was obtained by
adding each SNP to a logistic regression model containing the data
for the other four SNPs. MAF = Minor Allele Frequency; OR =
Odds Ratio; 95% CI = 95% Confidence Interval; df = degree of
freedom. Adapted from Nejentsev S, Walker N, Riches D, Egholm
M, Todd JA, (2009). Rare variants of IFIH1, a gene implicated in
antiviral responses, protect against type 1 diabetes. Science 324:
387-389.
Found at: doi:10.1371/journal.pone.0012646.s001 (0.04 MB
DOC)
Table S2 Expression of IFIH1 mRNA is not altered by the SNP,
rs35744605 (Glu627X), that encodes for a premature stop codon.
Donor 7 and 8 are control individuals and donor 9 and 10 are
heterozygous for rs35744605 (Glu627X). Delta Ct is calculated
using the IFIH1 qPCR minus the single copy gene b2
microglobulin (B2M) qPCR.
Found at: doi:10.1371/journal.pone.0012646.s002 (0.03 MB
DOC)
Table S3 Genotypes of donors used in functional assays.
Found at: doi:10.1371/journal.pone.0012646.s003 (0.05 MB
DOC)
Table S4 Primer and probe sequences.
Found at: doi:10.1371/journal.pone.0012646.s004 (0.03 MB
DOC)
Figure S1 Recombination rate in the IFIH1 gene region on
chromosome 2. Genome-wide recombination rate from Phase 2
HapMap, estimated from phased haplotypes in HapMap Release
22 (NCBI 36), remapped to GRCh37 and presented in T1DBase.
Hulbert EM, et al. (2007). T1DBase: integration and presentation
of complex data for type 1 diabetes research. Nucleic Acids Res
35: D742-746.
Found at: doi:10.1371/journal.pone.0012646.s005 (0.10 MB TIF)
Figure S2 Schematic presentation of the IFIH1 protein (green),
its domains (yellow) and T1D variants. The four rare variants,
rs35667974/Ile923Val, rs35337543/IVS8+1, rs35744605/Glu627X,
and rs35732034/IVS14+1 and the common variant, rs1990760/
Thr946Ala, that are independently associated with T1D and their
positions are shown. CARD - caspase recruitment domain. Adapted
from Nejentsev S, Walker N, Riches D, Egholm M, Todd JA, (2009).
Rare variants of IFIH1, a gene implicated in antiviral responses,
protect against type 1 diabetes. Science 324: 387-389.
Found at: doi:10.1371/journal.pone.0012646.s006 (0.12 MB TIF)
Figure S3 No allele specific bias was observed in IFIH1 pre
mRNA transcript using poly A selected or fragmented cDNA with
rs1990760 or rs3747517 ASE assays. Sign-rank test oligo-dT
samples versus genomic P=0.12 and fragmented cDNAs versus
genomic P=0.60.
Found at: doi:10.1371/journal.pone.0012646.s007 (0.10 MB TIF)
Figure S4 Pre mRNA levels of IFIH1 and IFNB1, the gene
encoding IFN-b, increase and plateau in PBMCs stimulated with
1000 U/ml of IFN-b for 6 hours. Ct values for the gene specific
assays are normalised using a qPCR assay for b2 microglobulin.
Found at: doi:10.1371/journal.pone.0012646.s008 (0.10 MB TIF)
Figure S5 No allele specific bias is observed using the rs1990760
ASE assay in cDNA of fragmented RNA primed with hexamer
from PBMCs stimulated with IFN-b (P=0.64).
Found at: doi:10.1371/journal.pone.0012646.s009 (0.10 MB TIF)
Figure S6 Mean fluorescence intensity (MFI) of IFIH1 protein
expression in resting monocytes, B and T cells of the three paired
control individuals.
Found at: doi:10.1371/journal.pone.0012646.s010 (0.10 MB TIF)
Figure S7 Expression of IFIH1 protein increases with IFN-b
stimulation at 6 hours and overnight in monocytes, B and T cells
of one paired control individual.
Found at: doi:10.1371/journal.pone.0012646.s011 (0.10 MB TIF)
Figure S8 The reduced expression of IFIH1 protein due to the
stop codon SNP, rs35744605 (Glu627X), is amplified with IFN-b
stimulation within the cell subsets. Normalised MFI of IFIH1
expression within monocytes, B and T cells stimulated with
1,000 U/ml IFN-b overnight. The MFI of individuals heterozy-
gous for the stop codon SNP is normalised to the MFI of the
paired control individual.
Found at: doi:10.1371/journal.pone.0012646.s012 (0.11 MB TIF)
Figure S9 Reduced expression of IFIH1 due to the stop codon
SNP, rs35744605 (Glu627X), may be observed by western blot of
protein lysates from resting PBMCs and PBMCs stimulated with
IFN-b for 6 hours and overnight.
Found at: doi:10.1371/journal.pone.0012646.s013 (0.10 MB TIF)
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